Paul Moore
Chief Scientific Officer Zymeworks
Dr. Moore joined Zymeworks in July 2022 serving as Chief Scientific Officer and heading early stage RnD efforts focused on the development of next generation ADCs and multispecifics, with multiple new therapeutics entered or on track to enter clinical development. Paul has over 25 years of US-based experience in biologics drug discovery and development in biotechnology research, with his career efforts leading to the discovery and development of a range of FDA-approved and clinical-stage biologics for patients. Before joining Zymeworks, he served as Vice President, Cell Biology, and Immunology at MacroGenics, where he worked on the development of numerous clinical stage compounds and scientific collaborations with a range of pharmaceutical partners. He began his biotech career at Human Genome Sciences (HGS), holding several titles within research culminating in Director of Lead Product Development, where he managed various genomic-based target discovery programs including efforts that led to the discovery, development, approval, and commercialization of Benlysta (belimumab) for the treatment of systemic lupus erythematosus. Dr. Moore received his PhD from the University of Glasgow, performed post-doctoral work at the Roche Institute of Molecular Biology in Nutley, New Jersey, and also holds a degree in Biotechnology from the University of Strathclyde. He has an extensive research record co-authoring over 80 peer-reviewed manuscripts and is a named co-inventor on over 50 issued US patents.
Seminars
Thursday 9th July 2026
Optimising Multispecific Antibody Design for Therapeutic Application
11:10 am
- By incorporating multifunctionality into a single molecule and leveraging novel mechanisms of biological activity, multispecific antibodies have the potential to provide modes of therapeutic intervention not feasible with traditional monoclonal antibodies or their combination
- Imperative to the design of multispecifics however is the optimal integration of each individual binding component within the multispecific structure to yield optimal biological activity, while maintaining desired pharmacological and manufacturing properties. The Azymetric platform, provides a convenient solution for generating efficient stable heterodimer antibody assembly to enable a multispecific platform adaptable to different formats supporting a range of applications
- Case studies covering examples of Azymetric based therapeutics will be shared ranging from Ziihera, approved for the treatment of HER2+ Billiary Tract cancer, to bispecific ADCs, to next generation T-cell engagers incorporating conditional costimulation applicable across solid and hematological cancers. Emphasis will be placed on the importance of matching format to desired biological activity and mode of therapeutic intervention to yield differentiated drug candidates.
